Lea en español

Essure Birth Control Medication

GL-Essure-BC-SpanishThe Essure birth control procedure, approved in the United States in 2002, is an allegedly permanent, but less invasive means of surgical sterilization. With the Essure product, marketed by Bayer AG’s affiliate Conceptus, Inc., a woman has a coil inserted into each fallopian tube, blocking the tubes and preventing conception.

The U.S. Food and Drug Administration (FDA), though, has received more than 5,000 complaints linked to the Essure insert, with users reporting a lengthy list of side effects, including seven deaths. Among the adverse health consequences acknowledged by the FDA are:

  • Punctures or perforations in the uterine wall caused by the insert
  • Failure of the device, leading to unwanted pregnancy
  • Changes in menstrual cycles
  • Nausea, vomiting, cramping and vaginal bleeding
  • Allergic reactions to materials in the insert
  • Weight gain
  • Hair loss
  • Numbness
  • Anxiety or depression

After recent complaints to the FDA, federal investigators have determined that Bayer actively concealed information from the FDA during the product’s approval process, and engaged in other negligence, including using substandard materials when manufacturing the product. Mass tort litigation has been filed naming Bayer and Conceptus as defendants.

If you or someone you love has suffered injury using the Essure birth control product, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

FCC Votes to End Net Neutrality

Most people can agree that the internet is playing an increasingly important role in our everyday li…

03 Jan 2018, Wednesday

Merry Christmas From GetLegal

22 Dec 2017, Friday

Defamation: What You Need to Know

With the rise of social media, there is no longer a traditional “reasonable expectation of privacy…

15 Dec 2017, Friday